Diabetes Insipidus Symptoms Causes and Management Approaches

Most people who hear "diabetes insipidus" assume it must be related to blood sugar. It is not. Despite sharing a word with diabetes mellitus, diabetes insipidus is a completely separate condition involving an entirely different hormonal system — one that controls how the kidneys manage water, not how the body processes glucose. The two conditions share only the symptom of excessive urination, and the similarity ends there.

Diabetes insipidus (DI) is characterised by the production of large volumes of very dilute, odourless ("insipid") urine — sometimes 3 to 20 litres per day — accompanied by intense, constant thirst. It is caused by a deficiency or insensitivity to a hormone called antidiuretic hormone (ADH, also called vasopressin) that normally signals the kidneys to retain water. Understanding the type of DI — central or nephrogenic — is essential because the causes and management approaches are completely different.

Quick Takeaways

• Diabetes insipidus is not related to blood sugar or diabetes mellitus — it is a disorder of water regulation caused by deficiency of or resistance to antidiuretic hormone (ADH/vasopressin).
• The hallmark symptoms are polydipsia (extreme thirst) and polyuria (very large volumes of dilute urine, up to 20 litres per day).
• There are two main types: central DI (the brain does not produce enough ADH) and nephrogenic DI (the kidneys do not respond to ADH).
• Without access to water, DI can cause severe, life-threatening hypernatraemia (dangerously high blood sodium) within hours.
• Treatment depends on the type: central DI is managed with desmopressin (synthetic ADH); nephrogenic DI is managed by addressing the underlying cause and specific medications.

Understanding Antidiuretic Hormone (ADH) and What Goes Wrong

ADH (vasopressin) is produced in the hypothalamus — a region of the brain — and stored in the posterior pituitary gland, from where it is released into the bloodstream in response to rising blood osmolality (concentration) or falling blood pressure. Its primary action is to bind to receptors in the collecting ducts of the kidneys, instructing them to reabsorb water from the forming urine back into the bloodstream, thereby concentrating the urine and conserving body water.

When this system fails — either because insufficient ADH is produced (central DI) or because the kidneys fail to respond to ADH (nephrogenic DI) — the collecting ducts remain "unresponsive" and large volumes of dilute urine are excreted. The body detects the rising blood concentration and triggers intense thirst, driving compensatory fluid intake. A person with DI who has adequate access to water can maintain reasonable fluid balance through this thirst mechanism, though with the exhausting burden of constant drinking and frequent urination. A person with DI who is denied access to water — due to surgery, illness, or incapacity — can develop fatal hypernatraemia (elevated blood sodium) very quickly.

Types and Causes of Diabetes Insipidus

Central (Neurogenic) DI — The Brain Cannot Produce Enough ADH

Central DI occurs when the hypothalamus or posterior pituitary is damaged or destroyed, impairing ADH production or release. It is the most common type of DI encountered in clinical practice. Causes include:

• Head trauma — including surgical procedures near the pituitary gland (transsphenoidal surgery for pituitary tumours is a well-recognised cause, with post-surgical DI occurring in 15–20% of pituitary surgeries).
• Pituitary or hypothalamic tumours — including craniopharyngioma (more common in children and young adults), germinoma, and metastatic brain tumours.
• Neurosurgery and radiation therapy — damage to the hypothalamic-pituitary axis.
• Infections — meningitis, encephalitis, and tuberculosis affecting the base of the brain.
• Autoimmune conditions — autoimmune hypophysitis (inflammation of the pituitary gland), where the immune system attacks pituitary tissue.
• Sarcoidosis — granulomatous infiltration of the hypothalamus or pituitary.
• Ischaemic damage — Sheehan's syndrome (pituitary infarction following postpartum haemorrhage).
• Idiopathic — in a significant proportion of central DI cases, particularly in adults, no identifiable cause is found. This is called idiopathic central DI and typically requires periodic MRI surveillance for an occult underlying tumour.

Nephrogenic DI — The Kidneys Cannot Respond to ADH

Nephrogenic DI occurs when ADH levels are normal or high, but the kidneys fail to respond to it. The ADH receptor (V2 receptor) or the aquaporin-2 water channel through which water enters the collecting duct cells is abnormal. Causes include:

• Chronic kidney disease — reduced tubular function impairs the concentrating mechanism.
• Electrolyte abnormalities — hypercalcaemia (high blood calcium) and hypokalaemia (low blood potassium) both impair the kidneys' ability to respond to ADH.
• Medications — lithium carbonate (widely used for bipolar disorder) is the most important drug-induced cause of nephrogenic DI, affecting 20–40% of long-term lithium users. Other drugs include demeclocycline, amphotericin B, and foscarnet.
• Congenital nephrogenic DI — a rare X-linked condition caused by mutations in the AVPR2 gene (encoding the V2 receptor) or the AQP2 gene (encoding aquaporin-2), presenting in male infants with severe DI from birth.
• Sickle cell disease — can damage the kidney's concentrating mechanism.

Gestational DI — A Temporary Pregnancy-Related Form

A transient form of DI can occur during pregnancy, caused by elevated levels of vasopressinase — an enzyme produced by the placenta that breaks down ADH faster than the mother's hypothalamus can replace it. Gestational DI typically resolves within 4–6 weeks after delivery. It is important to recognise because it requires management with desmopressin (which is not broken down by vasopressinase) rather than other treatments.

Primary Polydipsia — Not True DI, But Often Confused

Primary polydipsia (also called psychogenic polydipsia or dipsogenic DI) is a condition in which excessive water intake — driven by a primary abnormality in thirst perception, psychiatric conditions (particularly schizophrenia), or certain medications — causes dilute urine that resembles DI. The distinction is critical because management is opposite: DI requires ADH or water supplementation, while primary polydipsia requires restriction of fluid intake. A water deprivation test (described below) differentiates these conditions.

Symptoms of Diabetes Insipidus

Polyuria — The Defining Symptom

The hallmark of DI is the production of very large volumes (3–20 litres per day in complete DI) of very dilute, pale, odourless urine. Patients urinate frequently — multiple times per hour in severe cases — including throughout the night (nocturia), significantly disrupting sleep. The urine specific gravity is very low (below 1.005) and urine osmolality is typically below 300 mOsm/kg, reflecting extreme dilution.

Polydipsia — Intense Compensatory Thirst

Compensatory thirst in DI is intense, constant, and specifically directed toward cold water in many patients. It is not the ordinary thirst of mild dehydration — it is a relentless, difficult-to-satisfy drive to drink that significantly interferes with daily life, work, and sleep. Patients describe being unable to travel far from a water source and waking multiple times per night to drink.

Consequences of Dehydration and Hypernatraemia

If fluid intake does not match urine output — due to restricted access, nausea, reduced consciousness, or being unaware of the diagnosis — the blood sodium concentration rises rapidly (hypernatraemia). Symptoms of hypernatraemia include irritability, muscle weakness, confusion, and — in severe cases — seizures and coma. This is the acute danger of unmanaged DI, particularly in children, the elderly, and hospitalised patients.

In infants with congenital nephrogenic DI, who cannot communicate thirst or access water independently, hypernatraemia is a particular risk and can cause permanent neurological damage if not recognised and managed rapidly.

Diagnosis: How Diabetes Insipidus Is Confirmed

The Water Deprivation Test

The water deprivation test is the standard diagnostic procedure for suspected DI. Under closely monitored conditions (in hospital), the patient's fluid intake is restricted while urine and blood are collected at intervals to measure their concentrations. A normal person's urine concentrates markedly as blood osmolality rises. In DI, the urine remains dilute despite rising blood concentration — confirming the diagnosis. The test is completed with administration of desmopressin to determine whether the kidneys can respond (distinguishing central from nephrogenic DI). This test carries risk if not performed under medical supervision and must not be attempted independently.

Treatment and Management Approaches

Central DI: Desmopressin (DDAVP)

The primary treatment for central DI is desmopressin (DDAVP — 1-desamino-8-D-arginine vasopressin), a synthetic analogue of ADH that replaces the deficient hormone. It is available as nasal spray, intranasal drops, sublingual tablets, and oral tablets. Desmopressin binds to the V2 receptor in the kidney collecting duct, mimicking the water-retaining action of ADH and dramatically reducing urine output within 1–2 hours of administration.

Desmopressin dosing is highly individualised — the dose and frequency must be titrated by a Fortis endocrinologist based on urine output, thirst response, and serum sodium levels. Over-treatment with desmopressin can cause hyponatraemia (dangerously low sodium) by retaining too much water. Patients must be monitored with regular serum sodium measurements and should have clear guidance from their physician on what to do if they become unwell, undergo surgery, or develop vomiting.

Nephrogenic DI: Addressing the Cause

Nephrogenic DI does not respond to desmopressin because the kidney's ADH receptor is unresponsive. Management focuses on addressing the underlying cause:

• Stopping the causative medication: if lithium or another drug is responsible, stopping or reducing the dose (in consultation with the prescribing physician) may improve or resolve DI over weeks to months. Lithium-induced nephrogenic DI may not fully reverse even after cessation.
• Correcting electrolyte abnormalities: hypercalcaemia and hypokalaemia causing nephrogenic DI should be corrected under medical supervision.
• Thiazide diuretics (paradoxical effect): low-dose hydrochlorothiazide or indapamide, counterintuitively, can reduce urine output in nephrogenic DI by causing mild sodium depletion that increases proximal tubule water reabsorption. This is prescribed under specialist supervision with regular sodium and potassium monitoring.
• Indomethacin (a non-steroidal anti-inflammatory drug) may be added to thiazide therapy in some cases of nephrogenic DI under specialist guidance.
• Low-salt, low-protein diet: reduces the kidneys' obligatory solute excretion and can reduce urine volumes.

Gestational DI: Desmopressin During Pregnancy

Desmopressin is safe in pregnancy and is the treatment of choice for gestational DI. Natural ADH is destroyed by placental vasopressinase, but desmopressin is resistant to this enzyme. The condition typically resolves within 4–6 weeks postpartum, at which point desmopressin can be gradually withdrawn under medical supervision.

Living With Diabetes Insipidus

With correct diagnosis and appropriate treatment, most people with DI live full, active lives. Key management principles include:

• Always carry a medical alert card or bracelet identifying DI and current medications — critical in emergencies where you cannot communicate your condition.
• Inform all healthcare providers of your DI diagnosis before any surgical procedure, as surgery-related fluid management requires specialist input to avoid both dehydration and dangerous overhydration on desmopressin.
• Maintain consistent desmopressin timing as prescribed — erratic dosing causes unpredictable urine output fluctuations.
• Monitor sodium levels at the frequency recommended by your Fortis endocrinologist — hyponatraemia from over-treatment is the main medication risk.
• Travel with an adequate supply of desmopressin — storage requirements vary by formulation; check your prescription label.